(αs)-α-甲基-4-(1-甲基乙基)-苯甲胺 | 68285-22-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: (αs)-α-甲基-4-(1-甲基乙基)-苯甲胺
• 中文别名: (ΑS)-Α-甲基-4-(1-甲基乙基)-苯甲胺
• 英文名称: (S)-1-(4-isopropylphenyl)ethylamine
• 英文别名: (S)-1-(4-Isopropylphenyl)ethanamine；(1S)-1-(4-propan-2-ylphenyl)ethanamine
• CAS: 68285-22-3
• 化学式: C₁₁H₁₇N
• mdl: MFCD06762199
• 分子量: 163.263
• InChiKey: UHAQMLODFYUKOM-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P501,P264,P280,P303+P361+P353,P301+P330+P331,P363,P304+P340+P310,P305+P351+P338+P310,P405
• 危险品运输编号：
  2735
• 危险性描述：
  H314

反应信息

• 作为反应物：
  描述：

  (αs)-α-甲基-4-(1-甲基乙基)-苯甲胺 在 palladium on activated charcoal 氢气 作用下， 以 四氢呋喃 、 乙醇 为溶剂， -30.0 ℃ 、101.33 kPa 条件下， 反应 1.0h， 生成 [4-[(2S)-2-acetamido-3-[[(2S)-4-methyl-1-oxo-1-[[(1S)-1-(4-propan-2-ylphenyl)ethyl]amino]pentan-2-yl]amino]-3-oxopropyl]phenyl] dihydrogen phosphate
  参考文献：
  名称：

  Phosphotyrosine-Containing Dipeptides as High-Affinity Ligands for the p56^lck SH2 Domain

  摘要：

  Src homology-2 (SH2) domains are noncatalytic motifs containing approximately 100 amino acid residues that are involved in intracellular signal transduction. The phosphotyrosine-containing tetrapeptide Ac-pYEEI binds to the SH2 domain of p.56(lck) (Lck) with an affinity of 0.1 mu M. Starting from Ac-pYEEI, we have designed potent antagonists of the Lck SH2 domain which are reduced in peptidic character and in which the three carboxyl groups have been eliminated. The two C-terminal amino acids (EI) have been replaced by benzylamine derivatives and the pY + 1 glutamic acid has been substituted with leucine. The best C-terminal fragment identified, (S)-1-(4-isopropylphenyl)ethylamine, binds to the Lck SH2 domain better than the C-terminal dipeptide EI. Molecular modeling suggests that the substituents at the 4-position of the phenyl ring occupy the pY + 3 lipophilic pocket in the SH2 domain originally occupied by the isoleucine side chain. This new series of phosphotyrosine-containing dipeptides binds to the Lck SH2 domain with potencies comparable to that of tetrapeptide 1.

  DOI：

  10.1021/jm980612i
• 作为产物：
  描述：

  (S)-2-(4'-isopropylphenyl) propionic acid 在 palladium on activated charcoal 二苯基膦叠氮化物 、 氢气 、 三乙胺 作用下， 以 乙醇 为溶剂， 反应 18.75h， 生成 (αs)-α-甲基-4-(1-甲基乙基)-苯甲胺
  参考文献：
  名称：

  Phosphotyrosine-Containing Dipeptides as High-Affinity Ligands for the p56^lck SH2 Domain

  摘要：

  Src homology-2 (SH2) domains are noncatalytic motifs containing approximately 100 amino acid residues that are involved in intracellular signal transduction. The phosphotyrosine-containing tetrapeptide Ac-pYEEI binds to the SH2 domain of p.56(lck) (Lck) with an affinity of 0.1 mu M. Starting from Ac-pYEEI, we have designed potent antagonists of the Lck SH2 domain which are reduced in peptidic character and in which the three carboxyl groups have been eliminated. The two C-terminal amino acids (EI) have been replaced by benzylamine derivatives and the pY + 1 glutamic acid has been substituted with leucine. The best C-terminal fragment identified, (S)-1-(4-isopropylphenyl)ethylamine, binds to the Lck SH2 domain better than the C-terminal dipeptide EI. Molecular modeling suggests that the substituents at the 4-position of the phenyl ring occupy the pY + 3 lipophilic pocket in the SH2 domain originally occupied by the isoleucine side chain. This new series of phosphotyrosine-containing dipeptides binds to the Lck SH2 domain with potencies comparable to that of tetrapeptide 1.

  DOI：

  10.1021/jm980612i

文献信息

• BENZYLAMINE DERIVATIVES
  申请人：KALVISTA PHARMACEUTICALS LIMITED

  公开号：US20160039752A1

  公开（公告）日：2016-02-11

  The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.

  本发明提供了式(I)的化合物：包括这些化合物的组合物；使用这些化合物进行治疗（例如在涉及血浆卡利肌酶活性的疾病或病症的治疗或预防中）；以及使用这些化合物治疗患者的方法；其中R1至R3，R5至R9，A，P，V，W，X，Y和Z的定义如本文所述。
• Data-Driven Prediction of Circular Dichroism-Based Calibration Curves for the Rapid Screening of Chiral Primary Amine Enantiomeric Excess Values
  作者：James R. Howard、Arya Bhakare、Zara Akhtar、Christian Wolf、Eric V. Anslyn

  DOI：10.1021/jacs.2c08127

  日期：2022.9.21

  chiroptical sensor for enantiomeric excess (ee) determination of chiral amines using a multivariate fit to electronic and steric parameters. These computationally derived parameters can be computed for nearly any amine and correlate well with the CD response of the 12 amines comprising the training set. The resulting model was used to accurately predict the CD response of a test set of chiral amines. Theoretical

  在这里，我们描述了对三组分手性传感器的圆二色性 (CD) 响应的预测，该传感器用于使用与电子和空间参数的多元拟合来确定手性胺的对映体过量 ( ee )。这些计算得出的参数几乎可以为任何胺计算，并且与构成训练集的 12 种胺的 CD 响应良好相关。所得模型用于准确预测一组测试手性胺的 CD 响应。然后创建理论校准曲线并用于确定未知ee溶液的ee。使用这种方法，与实验生成的校准曲线相比，ee测定的误差相差不到 10%。
• Benzylamine Derivatives
  申请人：KALVISTA PHARMACEUTICALS LIMITED

  公开号：US20170253561A1

  公开（公告）日：2017-09-07

  The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.
• US9670157B2
  申请人：——

  公开号：US9670157B2

  公开（公告）日：2017-06-06
• US9834513B2
  申请人：——

  公开号：US9834513B2

  公开（公告）日：2017-12-05